Marvel Biosciences Corp. (MRVL.V)
CAD 0.16
(10.34%)
CAD 0.16
(10.34%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 672.38 Thousand CAD | -26.4% |
| 2022 | 913.54 Thousand CAD | -62.99% |
| 2021 | 2.46 Million CAD | 733.87% |
| 2020 | 295.98 Thousand CAD | -29.06% |
| 2019 | 417.23 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 347.26 Thousand CAD | -51.17% |
| 2024 Q1 | 434.74 Thousand CAD | -35.34% |
| 2024 Q2 | 711.15 Thousand CAD | 63.58% |
| 2023 Q3 | 1.22 Million CAD | 90.91% |
| 2023 FY | 672.38 Thousand CAD | -26.4% |
| 2023 Q1 | 839.11 Thousand CAD | -8.15% |
| 2023 Q2 | 639.18 Thousand CAD | -23.83% |
| 2023 Q4 | 672.38 Thousand CAD | -44.9% |
| 2022 Q1 | 2.14 Million CAD | -12.9% |
| 2022 FY | 913.54 Thousand CAD | -62.99% |
| 2022 Q4 | 913.54 Thousand CAD | 27.89% |
| 2022 Q2 | 921.09 Thousand CAD | -57.15% |
| 2022 Q3 | 714.34 Thousand CAD | -22.45% |
| 2021 Q4 | 2.46 Million CAD | 529.32% |
| 2021 Q3 | 392.19 Thousand CAD | 0.0% |
| 2021 FY | 2.46 Million CAD | 733.87% |
| 2020 FY | 295.98 Thousand CAD | -29.06% |
| 2019 FY | 417.23 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Arch Biopartners Inc. | 1.17 Million CAD | 42.588% |
| Covalon Technologies Ltd. | 24.9 Million CAD | 97.3% |
| Hemostemix Inc. | 313.76 Thousand CAD | -114.297% |
| Universal Ibogaine Inc. | 6.31 Million CAD | 89.357% |
| Kane Biotech Inc. | 5.68 Million CAD | 88.164% |
| MedMira Inc. | 3.65 Million CAD | 81.587% |
| NervGen Pharma Corp. | 13.23 Million CAD | 94.92% |
| XORTX Therapeutics Inc. | 7.21 Million CAD | 90.674% |